Et enkeltdosis- forsøg med patienter med varierende grad af levercirrhose (Child- Pugh- klasse A, B og C) har ikke vist, at hepatisk svækkelse skulle have signifikant betydning for farmakokinetik for aripiprazol og dehydro- aripiprazol, men undersøgelsen omfattede kun 3 patienter med klasse C levercirrhose, hvilket er utilstrækkelig basis for en konklusion vedrørende metabolisk kapacitet.
A single-dose study in subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.